Healthcare entity
Of the tracked stories, 1 of 2 also mention AtriCure, the most common co-covered peer. The 30-day window averages about 0.5 stories each week. Each story carries 2 original sources on average, compared with 3.3 for the broader beat in this window.
Last mentioned: Mar 22, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 1 of 2 also mention AtriCure, the most common co-covered peer. The 30-day window averages about 0.5 stories each week. Each story carries 2 original sources on average, compared with 3.3 for the broader beat in this window. The 5 average consequence score is below the beat benchmark of 5.9 in the same window. Coverage clusters in market-trends, which accounts for 1 of those 2, with the remainder spread across 1 other category. We currently track 2 Healthcare stories that mention AxoGen, published between February 21, 2026 and March 22, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 598 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering AxoGen. Shared-story counts are live from our verified record — not editorial picks.
DAFNA Capital Management reduced its position in Axogen by approximately $6.5 million during the fourth quarter of 2025, following a period of significant outperformance. Despite the trim, Axogen remains a core holding for the fund as the medical device maker continues to capitalize on its 20% revenue growth and dominant position in the peripheral nerve repair market.
Source: fool.com · Jonathan Ponciano (us)
AxoGen (NASDAQ: AXGN) has received a significant rating upgrade to "Strong-Buy" from Wells Fargo, signaling robust institutional confidence in the peripheral nerve repair specialist. This move, coupled with price target hikes from Jefferies and positive outlooks from Citigroup, underscores a bullish sentiment for the company's clinical and commercial trajectory.
Source: Ticker Report · Watch List News
AxoGen is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
